source
- AbbVie’s eczema antibody shows statistically significant benefit in Phase 2 trialAbbVie presented Phase 2 results for its experimental eczema treatment, an anti‑IL‑13 antibody named Zumilokibart. The study met its primary endpoints, demonstrating statistically significant impr…
- Merck reports positive phase 2b results for anti-TL1A antibody in hidradenitis suppurativaMerck announced that its experimental anti-TL1A antibody achieved a positive outcome in a phase 2b study. The trial enrolled patients with moderate to severe hidradenitis suppurativa, a chronic in…